Pfizer building $465M sterile injectables plant at its Michigan site

Pfizer sign
Pfizer will break ground next year on a 400,000-square-foot, $465 million sterile manufacturing plant. (Tracy Staton)

Pfizer has committed to building a massive, $465 million sterile manufacturing plant at its site in Michigan that is expected to add 450 new jobs by the time it is fully operational.

Pfizer said on Monday that it expects to break ground next spring on the 400,000-square-foot facility in Portage, Michigan, with construction slated to be complete in 2021 and production to begin in 2024.

The plant will include multiple self-contained modular manufacturing lines, allowing the manufacturing line in each module to be entirely separate from all other manufacturing lines, Pfizer said.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“This investment is part of our overall plan announced in January to invest approximately $5 billion in U.S.-based capital projects as a result of the enactment of the Tax Cuts and Jobs Act,” Pfizer CEO Ian Read said in a release.

RELATED: Pfizer seeks big tax break for its massive Michigan manufacturing facility

Locally, the company has also received an $11.5 million local tax abatement from the Michigan Strategic Fund, Bloomberg reports

Pfizer said its Portage site is one of its primary facilities for sterile injectables, liquids and semisolid medicines, as well as active pharmaceutical ingredients. It currently manufactures more than 150 products. Its biggest product is Solu-Medrol, an injectable anti-inflammatory medicine. The 450 jobs it says it will add are in addition to the 2,200 employees already working at the site.

Suggested Articles

With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.